Member Info for chrishutch

That would be nice

And me ha

Just yet, could still work out.

Come on fab, let’s see you turn up now.

From fab

Unveiling the Power of Antibody Reformatting  

In the world of biomedical research, antibody reformatting stands as a groundbreaking advancement. But why is it so significant? 

Improved Therapeutics – Antibodies can be engineered into various formats to; 

- Enhance their binding affinity and specificity to difficult and smaller epitopes on their target antigen, thereby increasing their therapeutic efficacy. These modifications can also minimize off-target effects and adverse reactions, leading to safer and more effective treatments. 

- Trigger target Avidity in the form of a bi-specific, which can interact with more than one surface antigen; in turn, this can have boosted cytotoxic effects, because of the direct recruitment of effector cells to the site of the disease; and, in tumorigenic conditions and infections, have less resistance to development due to the matched targeting of two different antigens. 

- Increase temperature tolerance, pH stability and solubility by miniaturisation into the VHH format, as nanobodies are chemically stable over a much wider pH range and exhibit superior solubility over standard IgG. They are also less prone to temperature-based instability due to their unfolding under heating conditions being fully reversable.

Enhanced Diagnostic tools - Antibody reformatting can improve function and utility of precision antibodies used in diagnostic assays such as: 

- Increasing sensitivity of assays by utilising bivalent and multivalent formats which can result in a much higher sensitivity and specificity without increasing your signal-noise ratio. This leads to more accurate detection and monitoring of diseases, facilitating earlier and more reliable diagnoses. 

- Achieving multi-use assays by utilising multi-specific format antibodies which can trigger binding to various targets and allow for rapid testing against various forms of similar target proteins.

Facilitating Advanced Research - By providing a diverse array of antibody formats, reformatting allows researchers to design and implement novel experimental approaches. This versatility enables the study of complex biological systems and the development of innovative therapeutic strategies, expanding our understanding of disease mechanisms and potential treatments. 

Fusion Antibodies have extensive experience in reformatting a wide range of antibody formats to facilitate various research and therapeutic needs. Our capabilities include:  

- Full-length IgG antibodies 

- Fab fragments 

- ScFv (single-chain variable fragments) 

- Bispecific / Multispecific antibodies 

- Humanised antibodies 

- Bivalent / Multivalent an

Https://x.com/mrchrishutch/status/1806594889611637148?s=61

Haha

Re posted

Investment case

THE PAST

The way I see it is that the company went through a tough period, caused by being too focused on a particular area, and client base.

This focused client base was highly dependent on a constant flow of venture capital.

When VC dropped off across the board, the smaller companies (fusions clients) had to put projects on hold and therefore so did fusion.

This put fusion in a difficult place and led to a need for fusion to raise capital during very unfavourable market conditions.

The combination of these two issues caused a massive fall in share price and rightly so, which was not good for existing shareholders.

SURVIVE MODE

The board addressed these issues by reducing out goings, headcount and the directors agreed to be paid in shares.

They also diversified their client base to include venture capital but also blue chip organisations, research clientele, and branched into other areas such as veterinary.

They also have started a royalty program to achieve on going working capital.

This was a smart and needed move as it eliminates the past from reoccurring.

THRIVE MODE

To achieve this the company has been heavily promoting itself in the industry and signed with huge companies and organisations some of which are in the billionaire bracket as a result.

The smart speculation is that one very large antibody company has also signed a test contract with the purpose of branching into the therapeutic area. This is a gateway which could open many partnerships for both companies.

And of course having signed with USA Cancer research to validate their OPTIMAL at zero cost.

INVESTMENT CASE

This is a recovery trade at these levels. But one that has been derisked heavily now and provides an almost unbelievable opportunity to buy cheap stock,

The current share price is not attributing any value to fusions, tech, Intellectual property or the changes the company have made in their outgoings, cash position, royalties, grants, or stronger portfolio base.

They are fully funded into 2025 and like to be cash neutral to positive this year.

They have a working pipeline of sales which is converting to revenues and growing fast. The board are seeing a marked improvement across the sector and from the recent interviews it suggests the company has already turned a corner and are doing well.

I don’t think opportunities like this come along very often and it is certainly a buy and hold trade which could lead to a huge increase in value,

Maybe read my notes for a clearer understanding

They have a cash runway into 2025 and all work is funded

Https://www.linkedin.com/posts/dept-for-economy-ni_minister-conor-murphy-has-launched-action-activity-7211733772080136192-zixM?utm_source=share&utm_medium=member_ios

Sat just above support, has bounced from here twice before. Could be an opportunity for a side trade

Investment case

THE PAST

The way I see it is that the company went through a tough period, caused by being too focused on a particular area, and client base.

This focused client base was highly dependent on a constant flow of venture capital.

When VC dropped off across the board, the smaller companies (fusions clients) had to put projects on hold and therefore so did fusion.

This put fusion in a difficult place and led to a need for fusion to raise capital during very unfavourable market conditions.

The combination of these two issues caused a massive fall in share price and rightly so, which was not good for existing shareholders.

SURVIVE MODE

The board addressed these issues by reducing out goings, headcount and the directors agreed to be paid in shares.

They also diversified their client base to include venture capital but also blue chip organisations, research clientele, and branched into other areas such as veterinary.

They also have started a royalty program to achieve on going working capital.

This was a smart and needed move as it eliminates the past from reoccurring.

THRIVE MODE

To achieve this the company has been heavily promoting itself in the industry and signed with huge companies and organisations some of which are in the billionaire bracket as a result.

The smart speculation is that one very large antibody company has also signed a test contract with the purpose of branching into the therapeutic area. This is a gateway which could open many partnerships for both companies.

And of course having signed with USA Cancer research to validate their OPTIMAL at zero cost.

INVESTMENT CASE

This is a recovery trade at these levels. But one that has been derisked heavily now and provides an almost unbelievable opportunity to buy cheap stock,

The current share price is not attributing any value to fusions, tech, Intellectual property or the changes the company have made in their outgoings, cash position, royalties, grants, or stronger portfolio base.

They are fully funded into 2025 and like to be cash neutral to positive this year.

They have a working pipeline of sales which is converting to revenues and growing fast. The board are seeing a marked improvement across the sector and from the recent interviews it suggests the company has already turned a corner and are doing well.

I don’t think opportunities like this come along very often and it is certainly a buy and hold trade which could lead to a huge increase in value,

1 code there too. Director buy would light this up.

100%

Be nice to see this climb eh.

New website for optimal it seems about to come along

If this buying continues we at least will have a blue day

All worth a watch. Might as well have up to date facts.

All very bullish too.

Alone

Https://www.linkedin.com/posts/fusion-antibodies-plc_ab-ility-activity-7206985516116754433-ViiL?utm_source=share&utm_medium=member_ios

Well played, great price.